GGGrzegorz Grynkiewicz

Grzegorz Grynkiewicz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Grzegorz Grynkiewicz has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Synthetic genistein derivatives as modulators of glycosaminoglycan storage

    by Anna Kloska, Magdalena Narajczyk, Joanna Jakóbkiewicz-Banecka, Grzegorz Grynkiewicz, Wiesław Szeja, Magdalena Gabig-Cimińska, Grzegorz Węgrzyn

    Mucopolysaccharidoses (MPS) are severe metabolic disorders caused by accumulation of undegraded glycosaminoglycans (GAGs) in lysosomes due to defects in certain lysosomal hydrolases. Substrate reduction therapy (SRT) has been proposed as one of potential treatment procedures of MPS. Importantly, small molecules used in such a therapy might potentially cross the blood–brain barrier (BBB) and improve neurological status of patients, as reported for a natural isoflavone, 5, 7-dihydroxy-3- (4-hydroxyphenyl)-4 H-1-benzopyran-4-one, also known as genistein. Although genistein is able to cross BBB to some extent, its delivery to the central nervous system is still relatively poor (below 10% efficiency). Thus, we aimed to develop a set of synthetically modified genistein molecules and characterize physicochemical as well as biological properties of these compounds.


    • 19 September 2008
      • Vol. 60  (4) , 439-63

    Tropane alkaloids as medicinally useful natural products and their synthetic derivatives as new drugs.

    by Grzegorz Grynkiewicz, Maria Gadzikowska

    Secondary metabolites of Solanaceae plants, sharing tropane skeleton as a common structural feature, are sharply divided into two classes: tropine and ecgonine derivatives. The first group, represented by well known alkaloids: atropine and scopolamine, which are considered to be model anticholinergic drugs, continues to provide inspiration in the search for more selective muscarinic receptor antagonists. The second class accommodates one of the principal drugs of abuse, cocaine. Synthesis of much needed cocaine antagonists, despite extensive research, has not been particularly successful. Therefore, new concepts of cocaine abuse treatment resort to immunotherapy and biotechnology. Contemporary pharmaceutical industry manufactures over 20 active pharmaceutical substances containing tropane moiety in their structure, which are applied as mydriatics, antiemetics, antispasmodics, anesthetics and bronchodilators. There are two sources of raw materials for this industrial activity: natural products isolated from cultivated transgenic plants (mainly scopolamine and atropine from Australian Duboisia) and chemical synthesis based on common intermediate: tropinone, which can be further transformed by synthetic means to the following classes of compounds: tropine and its esters (tropeines), scopine and nortropine derivatives, and tropane quaternary ammonium salts. This survey focuses on new developments in chemistry and pharmacology of tropane derivatives, particularly in view of their prospective industrial applications as therapeutics.


  • Synthesis of the Sugar Moieties

    by Grzegorz Grynkiewicz, Wieslaw Szeja


    • 19 September 2003
      • Vol. 60  (2) , 133-8

    Preliminary evaluation of CNS effects of 6-O-substituted chelidonine derivatives.

    by Ewa Jagiełło-Wójtowicz, Anna Chodkowska, Maria Gadzikowska, Ewa Chojecka-Koryn, Grzegorz Grynkiewicz

    Eleven new derivatives of chelidonine I, obtained by functionalization of the alkaloid hydroxyl group, have been tested for CNS activity in mice exhibiting statistically significant effects.

    • 9 October 2002
      • Vol. 59  (2) , 149-60

    Tropane alkaloids in pharmaceutical and phytochemical analysis.

    by Maria Gadzikowska, Grzegorz Grynkiewicz

    Alkaloids with tropane skeleton, present in many species of Solanaceae family, constitute important raw materials for variety of pharmaceutical preparations. Although basic facts concerning chemistry and pharmacology of these compounds date back to XIX century, the wealth of data accumulated recently has challenged many established opinions, particularly in the field of biogenesis. Advances in analytical techniques which made this progress possible are discussed, in reference to contemporary requirements for specification of active pharmaceutical ingredients.